+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID04865887

Combination Therapy with Pembrolizumab and Lenvatinib for Advanced or Metastatic Cervical Cancer in a Phase II Clinical Trial

Led by Georgetown University · Updated on 2026-09-10

35

Participants Needed

4

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer who have not responded to first-line treatment. This phase II trial aims to determine the objective response rate of this combination therapy and assess whether it can overcome immunosuppression related to vascular endothelial growth factor VEGF to improve patient outcomes. Participants will receive pembrolizumab as a 200mg intravenous infusion every three weeks alongside daily oral doses of 20 mg lenvatinib. The study is conducted in two stages initially enrolling 11 patients to assess early response, followed by an additional 24 patients if early responses are promising, totaling 35 participants. Treatment continues according to the protocol, with evaluations throughout the study to decide on further investigation. During the study, participants will undergo regular evaluations including response assessments based on RECIST 1.1 criteria, safety monitoring for adverse events, and survival follow-ups. These assessments involve imaging, laboratory tests, and clinical evaluations at specified intervals, including every treatment cycle and extended follow-up up to two years. Researchers will closely track response duration, progression-free survival, overall survival, and treatment-related side effects to understand the therapys impact and safety.

CONDITIONS

Brief Title

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here